NM-404 I-131

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
NM-404 I-131
Accession Number
DB15244
Type
Small Molecule
Groups
Investigational
Description

NM-404 I-131 is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).

Structure
Thumb
Synonyms
  • I-131-CLR1404
Categories
Not Available
UNII
R048696O9L
CAS number
873438-88-1
Weight
Average: 641.626
Monoisotopic: 641.277345357
Chemical Formula
C29H53INO4P
InChI Key
ZOAIEFWMQLYMTF-YRKXUXMHSA-N
InChI
InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3/i30+4
IUPAC Name
18-[4-(¹³¹I)iodophenyl]octadecyl 2-(trimethylazaniumyl)ethyl phosphate
SMILES
C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCCCCC1=CC=C([131I])C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
13173778

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceTumors, Solid1
1CompletedTreatmentMalignancies1
1RecruitingTreatmentMultiple Myeloma (MM)1
1RecruitingTreatmentPediatric Brain Tumor / Pediatric Lymphoma / Pediatric Solid Tumors1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoplasmacytic Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Multiple Myeloma (MM) / Small Lymphocytic Lymphoma (SLL)1
2WithdrawnTreatmentGliomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.06e-05 mg/mLALOGPS
logP4.38ALOGPS
logP5.65ChemAxon
logS-7.8ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area58.59 Å2ChemAxon
Rotatable Bond Count24ChemAxon
Refractivity172.77 m3·mol-1ChemAxon
Polarizability69.9 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:03 / Updated on May 21, 2019 12:38